View in EDS HTML Full Text PDF Full Text

Considerations for an In Vitro, Cell-Based Testing Platform for Detection of Adverse Drug-Induced Inotropic Effects in Early Drug Development. Part 1: General Considerations for Development of Novel Testing Platforms.

Saved in:
Bibliographic Details
Title: Considerations for an In Vitro, Cell-Based Testing Platform for Detection of Adverse Drug-Induced Inotropic Effects in Early Drug Development. Part 1: General Considerations for Development of Novel Testing Platforms.
Authors: Guth BD; Department of Drug Discovery Sciences, Boehringer Ingelheim Pharma GmbH & Co KG, Biberach an der Riss, Germany.; PreClinical Drug Development Platform (PCDDP), North-West University, Potchefstroom, South Africa., Engwall M; Safety Pharmacology and Animal Research Center, Amgen Research, Thousand Oaks, CA, United States., Eldridge S; Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States., Foley CM; Department of Integrative Pharmacology, Integrated Sciences and Technology, AbbVie, North Chicago, IL, United States., Guo L; Laboratory of Investigative Toxicology, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD, United States., Gintant G; Department of Integrative Pharmacology, Integrated Sciences and Technology, AbbVie, North Chicago, IL, United States., Koerner J; Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, United States., Parish ST; Health and Environmental Sciences Institute, Washington, DC, United States., Pierson JB; Health and Environmental Sciences Institute, Washington, DC, United States., Ribeiro AJS; Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translation Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, United States., Zabka T; Department of Safety Assessment, Genentech, South San Francisco, CA, United States., Chaudhary KW; Global Safety Pharmacology, GlaxoSmithKline plc, Collegeville, PA, United States., Kanda Y; Division of Pharmacology, National Institute of Health Sciences, Kanagawa, Japan., Berridge B; National Toxicology Program, National Institute of Environmental Health Sciences, Durham, NC, United States.
Source: Frontiers in pharmacology [Front Pharmacol] 2019 Aug 09; Vol. 10, pp. 884. Date of Electronic Publication: 2019 Aug 09 (Print Publication: 2019).
Publication Type: Journal Article; Review
Journal Info: Publisher: Frontiers Media] Country of Publication: Switzerland NLM ID: 101548923 Publication Model: eCollection Cited Medium: Print ISSN: 1663-9812 (Print) Linking ISSN: 16639812 NLM ISO Abbreviation: Front Pharmacol Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 31447679
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Considerations for an In Vitro, Cell-Based Testing Platform for Detection of Adverse Drug-Induced Inotropic Effects in Early Drug Development. Part 1: General Considerations for Development of Novel Testing Platforms.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Guth+BD%22">Guth BD</searchLink>; Department of Drug Discovery Sciences, Boehringer Ingelheim Pharma GmbH & Co KG, Biberach an der Riss, Germany.; PreClinical Drug Development Platform (PCDDP), North-West University, Potchefstroom, South Africa.<br /><searchLink fieldCode="AU" term="%22Engwall+M%22">Engwall M</searchLink>; Safety Pharmacology and Animal Research Center, Amgen Research, Thousand Oaks, CA, United States.<br /><searchLink fieldCode="AU" term="%22Eldridge+S%22">Eldridge S</searchLink>; Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States.<br /><searchLink fieldCode="AU" term="%22Foley+CM%22">Foley CM</searchLink>; Department of Integrative Pharmacology, Integrated Sciences and Technology, AbbVie, North Chicago, IL, United States.<br /><searchLink fieldCode="AU" term="%22Guo+L%22">Guo L</searchLink>; Laboratory of Investigative Toxicology, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD, United States.<br /><searchLink fieldCode="AU" term="%22Gintant+G%22">Gintant G</searchLink>; Department of Integrative Pharmacology, Integrated Sciences and Technology, AbbVie, North Chicago, IL, United States.<br /><searchLink fieldCode="AU" term="%22Koerner+J%22">Koerner J</searchLink>; Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, United States.<br /><searchLink fieldCode="AU" term="%22Parish+ST%22">Parish ST</searchLink>; Health and Environmental Sciences Institute, Washington, DC, United States.<br /><searchLink fieldCode="AU" term="%22Pierson+JB%22">Pierson JB</searchLink>; Health and Environmental Sciences Institute, Washington, DC, United States.<br /><searchLink fieldCode="AU" term="%22Ribeiro+AJS%22">Ribeiro AJS</searchLink>; Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translation Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, United States.<br /><searchLink fieldCode="AU" term="%22Zabka+T%22">Zabka T</searchLink>; Department of Safety Assessment, Genentech, South San Francisco, CA, United States.<br /><searchLink fieldCode="AU" term="%22Chaudhary+KW%22">Chaudhary KW</searchLink>; Global Safety Pharmacology, GlaxoSmithKline plc, Collegeville, PA, United States.<br /><searchLink fieldCode="AU" term="%22Kanda+Y%22">Kanda Y</searchLink>; Division of Pharmacology, National Institute of Health Sciences, Kanagawa, Japan.<br /><searchLink fieldCode="AU" term="%22Berridge+B%22">Berridge B</searchLink>; National Toxicology Program, National Institute of Environmental Health Sciences, Durham, NC, United States.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101548923%22">Frontiers in pharmacology</searchLink> [Front Pharmacol] 2019 Aug 09; Vol. 10, pp. 884. <i>Date of Electronic Publication: </i>2019 Aug 09 (<i>Print Publication: </i>2019).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Review
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Frontiers+Media]%22">Frontiers Media] </searchLink><i>Country of Publication: </i>Switzerland <i>NLM ID: </i>101548923 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Print <i>ISSN: </i>1663-9812 (Print) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2216639812%22">16639812 </searchLink><i>NLM ISO Abbreviation: </i>Front Pharmacol <i>Subsets: </i>PubMed not MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=31447679
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.3389/fphar.2019.00884
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 884
    Titles:
      – TitleFull: Considerations for an In Vitro, Cell-Based Testing Platform for Detection of Adverse Drug-Induced Inotropic Effects in Early Drug Development. Part 1: General Considerations for Development of Novel Testing Platforms.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Guth BD
      – PersonEntity:
          Name:
            NameFull: Engwall M
      – PersonEntity:
          Name:
            NameFull: Eldridge S
      – PersonEntity:
          Name:
            NameFull: Foley CM
      – PersonEntity:
          Name:
            NameFull: Guo L
      – PersonEntity:
          Name:
            NameFull: Gintant G
      – PersonEntity:
          Name:
            NameFull: Koerner J
      – PersonEntity:
          Name:
            NameFull: Parish ST
      – PersonEntity:
          Name:
            NameFull: Pierson JB
      – PersonEntity:
          Name:
            NameFull: Ribeiro AJS
      – PersonEntity:
          Name:
            NameFull: Zabka T
      – PersonEntity:
          Name:
            NameFull: Chaudhary KW
      – PersonEntity:
          Name:
            NameFull: Kanda Y
      – PersonEntity:
          Name:
            NameFull: Berridge B
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 09
              M: 08
              Text: 2019 Aug 09
              Type: published
              Y: 2019
          Identifiers:
            – Type: issn-print
              Value: 1663-9812
          Numbering:
            – Type: volume
              Value: 10
          Titles:
            – TitleFull: Frontiers in pharmacology
              Type: main
ResultId 1